- Home
- EDIT vs NMAI Comparison
EDIT vs NMAI Comparison
Compare EDIT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | NMAI |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.8M | 458.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | NMAI |
|---|---|---|
| Price | $2.95 | $14.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.30 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 85.8K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.97 |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $11.99 |
| 52 Week High | $4.54 | $14.75 |
Technical Indicators
Market Signals| Indicator | EDIT | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 73.82 |
| Support Level | $2.40 | $13.59 |
| Resistance Level | $3.27 | N/A |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 73.39 | 97.81 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.